Paul Liknaitzky is Head of Clinical Psychedelic Research at Monash University, and Chief Principal Investigator on a program of psychedelic trials.
He is a joint Research Fellow within the Turner Institute and the Dept of Psychiatry at Monash University. Paul earned an Honours in Neuroscience and a PhD in Psychology from the University of Melbourne, and has Adjunct or Honorary appointments at St Vincent’s Hospital, the University of Melbourne, Swinburne University, and Deakin University.
He is an Investigator on a number of Australia’s first few approved psychedelic trials, coordinates Australia’s first applied psychedelic therapist training programs, obtained the first industry funding and partnership for psychedelics in Australia, and leads Australia’s first clinical psychedelic lab. His work is focused on developing a rigorous program of research in psychedelic medicine that seeks to evaluate therapeutic effects, innovate on treatment design, mitigate known risks, explore potential drawbacks, and understand therapeutic mechanisms.